ArticleDiabetes & metabolism journal2025

Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus.

Mijin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.